An intra-articular injection of LMW human serum albumin is safe and effective for knee OA .
This report has been verified
by one or more authors of the
original publication.
OrthoEvidence Journal (OE Journal) - ACE Report
OE Journal. 2014;2(11):18 PLoS One. 2014 Feb 3;9(2):e87910. doi: 10.1371/journal.pone.0087910. eCollection 2014.329 patients with symptomatic knee osteoarthritis (OA) were randomized to receive either Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) or saline vehicle solution, each at a dose of either 4 or 10 mL. The purpose of this study was to determine the analgesic efficacy and safety of LMWF-5A in this study population. Results indicated that both the 4-mL and 10-mL volumes of the LMWF-5A solution were safe and yielded significantly better pain scores, functional outcome, and overall assessment of disease severity, when compared to a saline vehicle solution. These effects were especially pronounced in patients with severe OA, and those who received a prior knee injection.
Was the allocation sequence adequately generated?
Was allocation adequately concealed?
Blinding Treatment Providers: Was knowledge of the allocated interventions adequately prevented?
Blinding Outcome Assessors: Was knowledge of the allocated interventions adequately prevented?
Blinding Patients: Was knowledge of the allocated interventions adequately prevented?
Was loss to follow-up (missing outcome data) infrequent?
Are reports of the study free of suggestion of selective outcome reporting?
Were outcomes objective, patient-important and assessed in a manner to limit bias (ie. duplicate assessors, Independent assessors)?
Was the sample size sufficiently large to assure a balance of prognosis and sufficiently large number of outcome events?
Was investigator expertise/experience with both treatment and control techniques likely the same (ie.were criteria for surgeon participation/expertise provided)?
Sì = 1
Incerto = 0,5
Non rilevante = 0
No = 0
La valutazione dei criteri di segnalazione valuta la trasparenza con cui gli autori riportano le caratteristiche metodologiche e sperimentali dello studio all'interno della pubblicazione. La valutazione è suddivisa in cinque categorie che vengono presentate di seguito.
4/4
Randomization
3/4
Outcome Measurements
4/4
Inclusion / Exclusion
4/4
Therapy Description
4/4
Statistics
Detsky AS, Naylor CD, O'Rourke K, McGeer AJ, L'Abbé KA. J Clin Epidemiol. 1992;45:255-65
L'Indice di Fragilità è uno strumento che aiuta l'interpretazione dei risultati significativi, fornendo una misura della forza di un risultato. L'Indice di Fragilità rappresenta il numero di eventi consecutivi che devono essere aggiunti a un risultato dicotomico per rendere il risultato non più significativo. Un numero piccolo rappresenta un risultato più debole, mentre un numero grande rappresenta un risultato più forte.
Perché questo studio era necessario ora?
The prevalence of knee osteoarthritis (OA) is on the rise. This increase - potentially attributable (in part) to the increasing rates of obesity within the population - in concerning, as knee OA can significantly impact a patient's quality of life. Currently, conservative treatment for this inflammatory condition may include intra-articular corticosteroid or hyaluronan injections, or non-steroidal anti-inflammatory drugs (NSAIDs); however, these approaches are not supported by high-quality evidence. As a result, human serum albumin (HSA) has been proposed as an alternative in the management of knee OA. This study was needed to establish the analgesic efficacy and safety of the Low Molecular Weight Fraction of 5% HSA (LMWF-5A) for the treatment of patients with knee OA.
Qual era la domanda di ricerca principale?
Is the Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) safe and effective for improving pain, stiffness, function and overall disease severity in patients with knee osteoarthritis?
- In general, LMWF-5A improved pain significantly more (-0.93) compared to the control solution (-0.72) (estimated difference: -0.25; 95% CI -0.08 to -0.41; p=0.004). This significant between-group difference was apparent at week 4 (p=0.03), week 6 (p=0.04) and week 12 (p=0.004), but not at weeks 2 (p=0.14), 8 (p=0.06) or 10 (p=0.11).
- Over time ending at week 12, the percentage of pain score reduction was significantly greater when patients were administered LMWF-5A (42.3%) compared to the control solution (31.7%) (p<0.05).
- Compared to patients receiving the saline vehicle solution, those receiving LMWF-5A had significantly superior Patient's Global Assessment (PGA) of disease severity scores (-0.87 vs -0.65; p=0.01), physical function (-0.78 vs -0.64; p=0.04) and pain at rest (-0.91 vs -0.70; p=0.004).
- Whether patients were administered LMWF-5A or the saline vehicle solution, there was no significant difference in the number of acetaminophen pills consumed (median 24.0 vs 34.0; p=0.09), or stiffness (p>0.05).
- In patients with severe OA, LMWF-5A had a significant pain improvement compared to the saline solution (-0.42; 95% CI -0.08 to -0.77; p=0.02). Furthermore, patients who had previously received a knee injection had a significantly better mean pain outcome with LMWF-5A compared to control, whereas this finding was borderline-significant in patients who did not receive a previous injection.
- Between the LMWF-5A and control in injection groups, there were no significant differences in total adverse events (41% vs 47%), treatment-related adverse events (10% vs 13%), or serious adverse events (5% vs 6%). No serious adverse event was considered to be study-related and no deaths occurred.
Che cosa devo ricordare di più?
In patients with knee osteoarthritis (OA), both the 4-mL and 10-mL volumes of the Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) were safe and yielded significantly better pain scores, functional outcome, and overall assessment of disease severity, when compared to a saline vehicle solution. These effects were especially pronounced in patients with severe OA, and those who had received a prior knee injection. Stiffness and the amount of rescue analgesics consumed were not significantly different between groups.
Come influenzerà l'assistenza ai miei pazienti?
Results from this study support the administration of a single, intra-articular injection of Low Molecular Weight Fraction of 5% human serum albumin (LMWF-5A) in the treatment of knee osteoarthritis (OA). This finding is promising in patients with severe OA, for whom the only other treatment alternative may be surgical intervention. Additional long-term studies, with larger sample sizes, are needed to confirm these results.
DISCLAIMER
Il contenuto di questa pagina è solo a scopo informativo e non intende sostituire la consulenza, la diagnosi o il trattamento medico professionale. Se ha bisogno di cure mediche, si rivolga sempre al suo medico o al pronto soccorso più vicino. Le opinioni, le convinzioni e i punti di vista espressi dalle persone sui contenuti presenti in questa pagina non riflettono le opinioni, le convinzioni e i punti di vista di OrthoEvidence.
0 di 4 articoli mensili GRATUITI sbloccati
